Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist immunotherapy resulting in synergic therapeutic e...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sathana Dushyanthen, Zhi Ling Teo, Franco Caramia, Peter Savas, Christopher P. Mintoff, Balaji Virassamy, Melissa A. Henderson, Stephen J. Luen, Mariam Mansour, Michael H. Kershaw, Joseph A. Trapani, Paul J. Neeson, Roberto Salgado, Grant A. McArthur, Justin M. Balko, Paul A. Beavis, Phillip K. Darcy, Sherene Loi
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/9dca7cf8454b4a3b9462fc4df89bf7de
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/9dca7cf8454b4a3b9462fc4df89bf7de

Ejemplares similares